Abstract: The present invention relates to compositions based on nanodispersions which are preferably further processed to electrospun fibers comprising such nanodispersions. The nanodispersions may optionally contain birch bark extract. The electrospun fibers can be used in particular for the treatment of wounds. For this purpose the compositions containing electrospun fibers are preferably applied as such or in a spray or a foam.

Abstract: The present invention is in the field of delivering an active substance to the oral cavity and relates to mucoadhesive active composition and corresponding mucoadhesive dosage form, which can deliver an active substance within the oral cavity, especially an orodispersible tablet for delivering probiotic substance. The present invention also relates to a method of producing the said composition and a method of processing the composition into a mucoadhesive dosage form, especially an orodispersible tablet. The present invention moreover relates to a system and a method for testing the mucoadhesion of a dosage form.

Abstract: The present disclosure relates to foams comprising outer birch bard extracts. Stable compositions thereof, as well as methods of producing such foams, and methods of using of such foams are also described herein. The foams of the present disclosure contain triterpenes, which are known to improve wound healing.

Abstract: The present invention is in the field of delivering an active substance to the oral cavity and relates to mucoadhesive active composition and corresponding mucoadhesive dosage form, which can deliver an active substance within the oral cavity, especially an orodispersible tablet for delivering probiotic substance. The present invention also relates to a method of producing the said composition and a method of processing the composition into a mucoadhesive dosage form, especially an orodispersible tablet. The present invention moreover relates to a system and a method for testing the mucoadhesion of a dosage form.

Abstract: The invention relates to a foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer (M1) and at least one further monomer.

Abstract: The present invention relates to the improved production of proteins, preferably enzymes such as lipases. In particular, the invention relates to a mutated signal peptide and nucleotide sequence encoding said signal peptide that results in an increased protein secretion. Further, the invention relates to a mutated promoter that results in an increased protein expression. It was surprisingly found that the combination of the mutated signal peptide and the mutated promoter act synergistically to result in an about 100-fold increased protein production. Nucleic acid molecules, expression vectors and host cells comprising the mutated signal peptide, mutated promoter, or the combination thereof are also encompassed by the invention. Finally, the invention relates to methods and uses of such nucleic acid molecules, expression vectors and host cells for protein preparation.

Abstract: The invention relates to a stabilization of fluid oil-based suspensions comprising a hydrophobic silica, and medicaments based on such suspensions.

Abstract: The invention relates to a foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer (M1) and at least one further monomer.

Abstract: The invention relates to novel radiotherapeutic formulations containing 224Ra and methods for their production. The invention discloses, in particular, radiotherapeutic formulations comprising at least one salt of the isotope 224Ra, which are characterized in that the content of other radionuclides, in particular, the respective content of certain longeval radionuclides does not exceed a specific numerical value in mBq/g. The invention also relates to a method for producing radiotherapeutic formulations of this type, which is characterized by the following steps: after at least one centrifugation of an aqueous suspension of the compound 228Th(OH)4 and optionally after the resuspension of the raw sediment obtained in said centrifugation, the precipitated 228Th(OH)4 sediment is separated. The supernatant solution of a 224Ra salt that has been obtained is subsequently subjected to sterile filtration and is then made up to the required dose.

Abstract: The invention relates to a foam formulation comprising an essentially emulsifier-free emulsion of the oil in water type, comprising an oil phase and a water phase.

Abstract: The invention relates to a stabilization of fluid oil-based suspensions comprising a hydrophobic silica, and medicaments based on such suspensions.

Abstract: With respect to the object of providing a filter element with a sufficiently high filtration capacity and easy deformability, a filter element, comprising a first component (1), a second component (2) and a pleated filter medium (3) interposed between the components (1, 2), the components (1, 2) being disposed at a distance due to the filter medium (3), is characterized in that the filter element (3) is made of a non-woven fabric and pleated such that a distance between the components (1, 2) can be reversibly reduced, at least in some regions, when a force is applied.

Abstract: The present invention is the preparation and use of an emulsion concentrate obtainable by drying an oil-in-water emulsion comprising a lipid phase, one or more oil-soluble polymers; an aqueous phase, one or more water-soluble polymers, one or more UV photoprotective filters and optionally further cosmetic or dermatological active ingredients, auxiliaries and additives, to produce a water content of from 0.1 to 20% by weight, based on the total weight of the dried preparation.

Abstract: A low-viscosity Pickering water-in-oil emulsion having a viscosity of less than 3000 mPa·s, comprising (1) an oil phase, (2) a water phase, (3) at least one type of microfine, inorganic metal oxide particles a) having an average particle size of less than 200 nm, b) exhibiting both hydrophilic and also lipophilic properties, c) dispersible both in lipophilic and also in hydrophilic liquids and d) optionally surface-coated, (4) 0.01 to 5% by weight of at least one polymeric nonionic and/or cationic thickener and (5) at most 0.5% by weight of one or more emulsifiers.

Abstract: The invention relates to novel radiotherapeutic formulations containing 224Ra and methods for their production. The invention discloses, in particular, radiotherapeutic formulations comprising at least one salt of the isotope 224Ra, which are characterized in that the content of other radionuclides, in particular, the respective content of certain longeval radionuclides does not exceed a specific numerical value in mBq/g. The invention also relates to a method for producing radiotherapeutic formulations of this type, which is characterized by the following steps: after at least one centrifugation of an aqueous suspension of the compound 228Th(OH)4 and optionally after the resuspension of the raw sediment obtained in said centrifugation, the precipitated 228Th(OH)4 sediment is separated. The supernatant solution of a 224Ra salt that has been obtained is subsequently subjected to sterile filtration and is then made up to the required dose.

Abstract: An oil-in-water emulsion preparation comprises oil, water, alcohol, at least one of an homeopathic active ingredient and an herbal active ingredient, and a cellulose ether. A method of preparing an emulsion and a use of the emulsion are also provided.